Purchase of shares by the Issuer's subsidiary and changes in the Capital Group

The Management Board of Farmacol S.A. – the Issuer - announces to have received, on 14 February 2012, the information from its subsidiary CEFARM Białystok S.A. with its registered office in Białystok that the subsidiary entered into the share purchase agreement with Mr Stefan Kuziel to buy 50 shares with the par value of PLN 100.00 (in words: one hundred zlotys) each and with the total value of PLN 5,000.00 (in words: five thousand zlotys) for all shares, representing 100% of the share capital and conferring 100% votes at the Shareholders Meeting of the company operating under the business name: **SK-FARM Sp.z.o.o**. in Katowice registered in the District Court Katowice-Wschód in Katowice, 8th Commercial Division of the National Court Register under National Court Register Number (KRS) 0000428810. The purchase price of 1 share was PLN 200.00 (in words: two hundred zlotys) and the total purchase price for all 50 shares was PLN 10,000.00 (in words: ten thousand zlotys).

The principal activity of the new company will be the retail sale of pharmaceutical products and medical materials in pharmacies owned by the company, i.e. the activity is compatible with the main area of the activity of CEFARM Białystok S.A.

The share purchase in the aforementioned company was financed with equity and the investment is of a long term nature.

Concurrently, the Issuer announces that on 14 December 2012 a share purchase agreement was executed by and between the Issuer and its subsidiary Przedsiębiortwo Zaopatrzenia Farmaceutycznego "CEFARM – KIELCE" S.A. to purchase 2,499 shares of A series, numbered from 0001 to 2499 with the par value of PLN 10.00 (in words: ten zlotys) each and with the total value of PLN 24,990.00 (in words: twenty four thousand and nine hundred ninety zlotys) representing 49.98% of the share capital and conferring 49.98% votes at the Shareholders Meeting of the company operating under the business name: Przedsiębiortwo Zaopatrzenia Farmaceutycznego "CEFARM – KIELCE" S.A. Spółka komandytowo - akcyjna w Katowicach registered in the District Court Katowice-Wschód in Katowice, 8th Commercial Division of the National Court Register, under the National Court Register Number [KRS] 0000374359. The purchase price of 1 share was equal to its par value i.e. PLN 10.00 and the total purchase price for all 2,490 shares was PLN 24,990.00 (in words: twenty four thousand and nine hundred ninety zlotys)

The principal activity of the purchased company will be the wholesale of pharmaceutical products and medical materials. The share purchase in the aforementioned company was financed with equity and the investment is of a long term nature.

The Issuer's Management Board also reveals to have received a decision of the District Court for Kraków – Śródmieście in Kraków, 12th Commercial Division of the National Court Register, dated 23 November 2012 by virtue of which the cancelation of liquidation and the change of the business name and the registered office of the Issuer's subsidiary company, which previously operated under the business name Farmacol Tarnów Spółka z ograniczoną odpowiedzialnością with the registered office in Tarnów was changed into **FARMACOL** - **KADRY Spółka z 0.0.** with the registered office in Katowice and registered in the National Court Register.

Signatures of duly authorised representatives of the company:

- 1. Andrzej Smuga President of the Management Board
- 2. Barbara Kaszowicz Vice-President of the Management Board

Legal basis: Par.7 in conjunction with Par 5.1.1 of the Minister of Finance's Regulation of 19 February 2009 on current and periodic information to be published by issuers of securities and conditions for recognition as equivalent of information whose disclosure is required under the laws of a non-member state (Journal of Laws of 28 February 2009) and pursuant to Art. 56.1.2 of the Act on Public Offering of 29 July 2005 on public offering, conditions governing the introduction of financial instruments to organised trading, and public companies.